Advertisement
The prestigious recognition was awarded to Dr. Fink for his pioneeringresearch related to the pathogenesis and treatment of sepsis, a seriousmedical condition characterized by widespread inflammation, due to infection.
Advertisement
Dr. Fink was the Founding Chairman of the Department of Critical CareMedicine at the University of Pittsburgh, the first such department at amedical school in the United States. Dr Fink also held other Universityappointments including Professor of Pharmacology, the Watson Professor ofSurgery, and Associate Vice-chancellor for Translational Research. Dr. Fink'sacademic research program was continuously funded by the National Institutesof Health for more than 20 years.
The Society of Critical Care Medicine, which bestowed the honor to Dr.Fink, is the leading professional organization dedicated to ensuringexcellence and consistency in the practice of critical care medicine. Withmore than 13,000 members worldwide, the Society is the only professionalorganization devoted exclusively to the advancement of multi-professionalintensive care through excellence in patient care, professional education,public education, research and advocacy.
Dr. Fink is an author or co-author of more than 250 peer-reviewedscientific publications, has edited or co-edited 13 textbooks and is currentlyan Associate Editor for two highly regarded scientific journals: the Journalof Pharmacology and Experimental Therapeutics and the Journal of LeukocyteBiology.
About Logical Therapeutics Inc.
Logical Therapeutics, Inc. is a privately held biotechnology company basedin Waltham, Massachusetts. Logical Therapeutics is developing drugs to treata variety of medical conditions that are caused by or are associated withexcessive inflammation, including various forms of arthritis, obesity and type2 diabetes mellitus. For more information on Logical Therapeutics, visit thecompany's website at www.logicaltherapeutics.com or by email [email protected]
SOURCE Logical Therapeutics, Inc.
